Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
WEBINAR: Optimizing method development for efficiency, throughput and data quality 0 days 11 hours 10 mins 39 secs REGISTER NOW

Emerging immuno-oncology therapies

19 Jul 2018
General interest

Current methods for the treatment of cancer include radiation, chemotherapy and surgical intervention, but alternative treatment modalities exist should these traditional methods prove unsuccessful. In this blog post, Dominic Warrino (KCAS; KS, USA), shares his insights into immuno-oncology, and discusses two case studies utilizing antibody drug conjugates and cellular therapies.

Click here to read the full blog post.

LB_Q3-spotlight-view

Top content

  • Webinar Q&A follow-up: A masterclass in advanced analytical assays for bioanalysis of oligonucleotides
  • New AI tool predicts multiple sclerosis drug response
  • Waters upgrade Xevo MRT performance: who doesn’t want sharper, faster imaging?

Related tags

cancer immuno-oncology protein
Previous article

Related articles

4 APR 2013 COLLABORATIONS AND MERGERS
John Hopkins University strikes deal with Advanced Cell Diagnostics
30 JUL 2014 GENERAL INTEREST
New method finds potential avenues in the diagnosis of cancer
5 AUG 2015 GENERAL INTEREST
Biomarker changes could identify future dementia patients
13 APR 2015 DRUG DEVELOPMENT
Bioanalysis of antibody–drug conjugates: American Association of Pharmaceutical Scientists antibody–drug conjugate working group position paper
3 DEC 2013 CLINICAL
Companies form partnership to develop companion diagnostic tests for cancer therapy
15 APR 2014 INTERVIEWS
Interview with Kelli Jonakin (AB SCIEX) on large molecule analysis by LC–MS
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 Bioanalysis Zone